Nucleic Acid and Peptide Aptamers as Potential Antiviral Drugs

Basit Öğe Kaydı
dc.authorscopusid8558322700
dc.authorscopusid57202028538
dc.authorscopusid57213828166
dc.authorscopusid57225108280
dc.authorscopusid55838812200
dc.contributor.authorEvran, Serap
dc.contributor.authorUğurlu, Özge
dc.contributor.authorMan, Ezgi
dc.contributor.authorGültan, Merve
dc.contributor.authorÖzyurt, Canan
dc.date.accessioned2024-09-19T15:43:35Z
dc.date.available2024-09-19T15:43:35Z
dc.date.issued2021
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractAptamers with target-specific binding properties have emerged as an alternative to antibodies. Nucleic acid aptamers are short single-stranded oligonucleotides that can fold into unique three-dimensional structures. Nucleic acid aptamers are selected from random libraries in vitro by using the SELEX (Systematic Evolution of Ligands by Exponential Enrichment) technology. Likewise, peptide aptamers are short peptides that can be selected in vitro by using different strategies including phage display, ribosome display, or mRNA display. Aptamers are superior to antibodies with regard to ease of production, high stability, small size, and low cost. Therefore, aptamers find broad use in different biotechnological and therapeutic applications. Among them, aptamer use in virus detection and antiviral therapy is one of the attractive applications. The present Covid-19 pandemic and life-threatening viral infections reveal the need for rapid therapeutic solutions that can efficiently target viral mechanisms. In this respect, the chapter is mainly focused on aptamers with antiviral activity, as well as the use of aptamers in viral detection platforms. First, we summarize aptamer selection technologies that can be performed in vitro. Among them, we briefly explain ribosome display, mRNA display and SELEX (Systematic Evolution of Ligands by Exponential Enrichment) technologies. Then, we review aptamers targeting viral proteins and viral invasion mechanisms. In addition, we give an overview of aptamers developed against viruses. We also discuss the major hurdles in aptamer use, as well as the strategies to improve the drug potential of aptamers. © 2021 Bentham Science Publishers.en_US
dc.identifier.doi10.2174/9789814998093121070003
dc.identifier.endpage45en_US
dc.identifier.issn2452-3208
dc.identifier.scopus2-s2.0-85130532843en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage1en_US
dc.identifier.urihttps://doi.org/10.2174/9789814998093121070003
dc.identifier.urihttps://hdl.handle.net/20.500.12483/14438
dc.identifier.volume7en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherBentham Science Publishersen_US
dc.relation.ispartofFrontiers in Clinical Drug Research - Anti Infectivesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAntiviral aptameren_US
dc.subjectAptasensoren_US
dc.subjectDiagnostic aptamersen_US
dc.subjectDNA aptameren_US
dc.subjectMRNA displayen_US
dc.subjectPeptide aptameren_US
dc.subjectRibosome displayen_US
dc.subjectRNA aptameren_US
dc.subjectSELEXen_US
dc.subjectTherapeutic aptamersen_US
dc.titleNucleic Acid and Peptide Aptamers as Potential Antiviral Drugsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu